.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,487,005

« Back to Dashboard

Claims for Patent: 8,487,005

Title:Tranexamic acid formulations
Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Inventor(s): Moore; Keith A. (Loveland, OH), Heasley; Ralph A. (Webster Grove, MO), Greiwe; Jeffrey S. (Ft. Thomas, KY), Facemire; John W. (Douglasville, GA), Modest; Jason D. (Minneapolis, MN)
Assignee: Ferring B.V. (NL)
Application Number:13/620,148
Patent Claims: 1. A tranexamic acid tablet formulation comprising: tranexamic acid or a pharmaceutically acceptable salt thereof; and a modified release material; wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 50% to about 95% by weight of the formulation; wherein the modified release material is present in an amount from about 5% to about 50% by weight of the formulation; and wherein said tablet formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by a USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37.+-.0.5.degree. C., of less than about 40% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 15 minutes, and not less than about 50% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 90 minutes.

2. The tranexamic acid tablet formulation of claim 1, wherein said tablet formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by a USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37.+-.0.5.degree. C., of less than about 40% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 15 minutes, less than about 70% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes, and not less than about 50% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 90 minutes.

3. The tranexamic acid tablet formulation of claim 1, wherein said formulation provides an in-vitro dissolution release rate of the tranexamic acid or pharmaceutically acceptable salt thereof, when measured by the USP 27 Apparatus Type II Paddle Method @ 50 RPM in 900 ml water at 37.+-.0.5.degree. C., of about 0% to about 40% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 15 minutes, from about 20% to about 60% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 30 minutes, from about 40% to about 65% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 45 minutes, from about 50% to about 95% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 60 minutes, and not less than about 60% by weight of the tranexamic acid or pharmaceutically acceptable salt thereof released at about 90 minutes.

4. The tranexamic acid tablet formulation of claim 1, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

5. The tranexamic acid tablet formulation of claim 1, wherein formulation provides a dose of about 650 mg of tranexamic acid per tablet.

6. The tranexamic acid tablet formulation of claim 5, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

7. The tranexamic acid tablet formulation of claim 1, wherein the modified release material comprises hydroxypropylmethylcellulose.

8. The tranexamic acid tablet formulation of claim 7, wherein formulation provides a dose of about 650 mg of tranexamic acid per tablet.

9. The tranexamic acid tablet formulation of claim 8, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

10. The tranexamic acid tablet formulation of claim 1, wherein the formulation is in the form of a matrix tablet which comprises a drug mixed together with a granulated modified release material.

11. The tranexamic acid tablet formulation of claim 10, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet.

12. The tranexamic acid tablet formulation of claim 11, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

13. The tranexamic acid tablet formulation of claim 1, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation.

14. The tranexamic acid tablet formulation of claim 1, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 80% by weight of the formulation.

15. The tranexamic acid tablet formulation of claim 1, wherein the modified release material is present in an amount from about 10% to about 35% by weight of the formulation.

16. The tranexamic acid tablet formulation of claim 1, wherein: the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation; the formulation is in the form of a matrix tablet which comprises a granulated drug mixed together with the modified release material and the formulation provides a dose of about 650 mg of tranexamic acid per tablet.

17. The tranexamic acid tablet formulation of claim 16, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

18. The tranexamic acid tablet formulation of claim 16, wherein the modified release material comprises hydroxypropylmethylcellulose.

19. The tranexamic acid tablet formulation of claim 18, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

20. An oral dosage form comprising a tranexamic acid tablet formulation according to claim 1 coated with a film.

21. The oral dosage form of claim 20, wherein the film comprises a film-forming agent present in an amount in the range from about 2% tablet weight to about 4% tablet weight.

22. The oral dosage form of claim 20, wherein the film comprises a film-forming agent forming agent that comprises a (diethylaminoethyl) methacrylate/methyl-butyl-methacrylate copolymer.

23. The oral dosage form of claim 22, wherein the film forming agent comprises Eudragit E.

24. The oral dosage form of claim 20, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

25. The oral dosage form of claim 20, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet.

26. The oral dosage form of claim 25, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

27. The oral dosage form of claim 20, wherein the modified release material comprises hydroxypropylmethylcellulose.

28. The oral dosage form of claim 27, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet.

29. The oral dosage form of claim 28, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

30. The oral dosage form of claim 20, wherein the formulation is in the form of a matrix tablet which comprises a drug mixed together with a granulated modified release material.

31. The oral dosage form of claim 30, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet.

32. The oral dosage form of claim 31, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

33. The oral dosage form of claim 20, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation.

34. The oral dosage form of claim 20, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 80% by weight of the formulation.

35. The oral dosage form of claim 20, wherein the modified release material is present in an amount from about 10% to about 35% by weight of the formulation.

36. The oral dosage form of claim 20, wherein: the tranexamic acid or pharmaceutically acceptable salt thereof is present in an amount from about 60% to about 90% by weight of the formulation; the formulation is in the form of a matrix tablet which comprises a granulated drug mixed together with the modified release material and the formulation provides a dose of about 650 mg of tranexamic acid per tablet.

37. The oral dosage form of claim 36, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

38. The oral dosage form of claim 36, wherein the modified release material comprises hydroxypropylmethylcellulose.

39. The oral dosage form of claim 38, wherein the tranexamic acid or pharmaceutically acceptable salt thereof is tranexamic acid.

40. A method of treating menorrhagia comprising administering to a patient in need of such treatment at least one tablet of the tranexamic acid formulation of claim 1, wherein the formulation provides a dose of about 650 mg of tranexamic acid per tablet.

41. A method of treating menorrhagia comprising administering to a patient in need of such treatment at least one oral dosage form according to claim 20, wherein the oral dosage form provides a dose of about 650 mg of tranexamic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc